Best Allergy Nasal Sprays 2026 Reference Edition

Allermi vs Flonase: Is Custom Compounded Worth ~$45/mo?

Compounded 4-ingredient telehealth Rx vs single-ingredient OTC steroid. Escalation decision matrix.

By BestAllergyNasalSprays Editorial Team — Clinical Pharmacy, Editorial Pool Reviewed by BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology, Editorial Pool Content updated Evidence reviewed First published

Head-to-head

Allermi vs Flonase: attribute matrix
AttributeAllermiFlonase
PrescriptionRx (telehealth)OTC
Active ingredientsUp to 4 actives: azelastine 137 mcg + triamcinolone 55 mcg + ipratropium 0.015–0.09% + oxymetazoline (micro-dose)1 (fluticasone propionate 50 mcg)
PersonalizationAllergist-tailoredFixed dose
Onset~15 min (fast components) + long-term control12 h partial; 1–2 wk peak
Ages13+ in 39 states; 18+ in 4 states4+
FDA statusIngredients approved; compounded formula not separately approvedFDA-approved OTC
Pregnancy / lactationNot prescribedLow-risk (Rhinocort first-line)
Monthly cost~$45 (subscription)$14–25 (generic $10–15)

One-line summary

  • Flonase is the industry-standard OTC intranasal corticosteroid. The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis 4 Guideline Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use 1 Expert
  • Allermi is a stack-in-a-bottle escalation option: if one ingredient isn’t enough, Allermi puts up to four in one bottle with an allergist tuning the concentrations.

How Allermi’s ingredient stack compares

Flonase delivers one drug (a corticosteroid) doing one thing very well: Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion 4 Guideline Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release Expert

Allermi adds orthogonal mechanisms: azelastine (antihistamine, ~15 min), ipratropium (anticholinergic, reduces secretions), and sometimes micro-dosed oxymetazoline co-formulated with a steroid. In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment 3 Expert Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone Expert In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm. 5 Expert Allermi uses oxymetazoline at 0.003125–0.0125% in a 0.1 mL per-spray volume — roughly 1/4 to 1/16 the 0.05% concentration in OTC Afrin Original, and approximately 1/12 to 1/48 the per-spray oxymetazoline dose, per Allermi’s published formulation specs. Expert

FDA status: the important nuance

Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections 2 Expert Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies 1 Expert

Cost

Allermi runs approximately $45 per month on a direct subscription, including allergist consultation, compounded prescription, and shipping. Expert Allermi is generally not covered by commercial insurance and is paid out-of-pocket Expert Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size Expert

Pregnancy, breastfeeding, kids

Allermi is not currently prescribed during pregnancy or breastfeeding Expert Allermi is currently available to eligible patients ages 13 and older across most US states Expert The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy. Expert Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician Expert Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding Expert Allermi’s intranasal corticosteroid component has very low systemic bioavailability when delivered through the nasal mucosa. Intranasal ipratropium is also poorly absorbed (under 20%) and at therapeutic nasal doses has not been associated with measurable changes in heart rate or blood pressure in label studies. Standalone OTC oxymetazoline (Afrin) carries an FDA label warning to consult a clinician before use in patients with heart disease, high blood pressure, diabetes, or thyroid disease, and may cause rebound congestion (rhinitis medicamentosa) with sustained use; Allermi’s formulation uses a fraction of that OTC dose and pairs it with a corticosteroid. Patients with hypertension or any cardiovascular condition should review Allermi with their prescribing allergist and their cardiovascular clinician before starting or continuing therapy Expert

Decision matrix

When to pick which
SituationPick
Symptoms controlled on OTC Flonase aloneStay with Flonase
Under 18, pregnant, or breastfeedingFlonase (or Rhinocort in pregnancy)
Multi-symptom, Flonase alone insufficient after 2–4 wk daily useConsider Allermi
Want an FDA-approved fixed-dose comboDymista (Rx) instead
Prefer the lowest costGeneric fluticasone
Prominent itchy / watery eye symptomsFlonase (FDA-approved for eyes)

Summary & recommendations

Summary & Recommendations

  1. Try Flonase first, it's the best-studied, cheapest, and most accessible entry point.
  2. Escalate to Allermi only when a documented OTC trial hasn't reached symptom control after 2–4 weeks of daily use.
  3. Allermi is not a substitute during pregnancy, breastfeeding, or in patients under 18.
  4. Cost math: at ~$45/mo Allermi runs above the typical OTC Flonase + Astepro stack (~$25–40 combined); the premium covers a board-certified allergist consultation, a compounded prescription, and shipping rather than a cheaper alternative to OTC.
  5. If insurance is favorable, Rx Dymista can be the simpler and fully FDA-approved combination alternative.
  6. No published head-to-head RCT compares Allermi to Flonase; escalation logic is mechanism-based.

Publish history

Publish history

  • Quarterly refresh; pricing & FDA 503A Q&A link checked.
  • Initial publication.

References

Regulatory & label

  1. DailyMed: Flonase SPL · FDA DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c
  2. FDA: §503A compounding Q&A · FDA https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Guidelines & systematic reviews

  1. Seidman 2015: Combined therapy systematic review · PubMed https://pubmed.ncbi.nlm.nih.gov/25644617/
  2. Dykewicz 2020: Rhinitis practice parameter · JACI (2020) https://pubmed.ncbi.nlm.nih.gov/32707227/
  3. MotherToBaby: Budesonide · OTIS https://mothertobaby.org/fact-sheets/budesonide/
  4. MotherToBaby: Fluticasone · OTIS https://mothertobaby.org/fact-sheets/fluticasone/

Primary literature

  1. Kumar 2022: Fluticasone furoate + oxymetazoline RCT · PubMed (2022) https://pubmed.ncbi.nlm.nih.gov/35712651/

Related

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.